Point-of-care hepatitis C testing and treatment strategy for people attending harm reduction and addiction centres for hepatitis C elimination

被引:18
|
作者
Forns, Xavier [1 ,2 ]
Colom, Joan [3 ]
Garcia-Retortillo, Montse [4 ]
Carles Quer, Joan [5 ]
Lens, Sabela [1 ,2 ]
Martro, Elisa [6 ,7 ]
Dominguez-Hernandez, Raquel [8 ]
Angel Casado, Miguel [8 ]
Buti, Maria [2 ,9 ]
机构
[1] Univ Barcelona, Hosp Clin Barcelona, Liver Unit, IDIBAPS, Barcelona, Spain
[2] Inst Carlos III, CIBERehd, Barcelona, Spain
[3] Agcy Publ Hlth Catalonia, Programme Prevent Control & Treatment HIV STIs &, Programme Subst Abuse, Barcelona, Spain
[4] Hosp Mar, Dept Gastroenterol, Liver Sect, Barcelona, Spain
[5] Univ Hosp Joan XXIII, Gastroenterol Dept, Tarragona, Spain
[6] Hosp Badalona Germans Trias & Pujol, Inst Invest Ciencies Salut Germans Trias & Pujol, Microbiol Dept, Lab Clin Metropolitana Nord, Badalona, Spain
[7] Inst Salud Carlos III, Biomed Res Networking Ctr Epidemiol & Publ Hlth C, Madrid, Spain
[8] Pharmacoecon & Amp Outcomes Res Iberia PORIB, Madrid, Spain
[9] Hosp Univ Vall dHebron, Internal Med Dept, Liver Unit, Barcelona, Spain
关键词
addiction centres; cascade of care; drug users; harm reduction services; hepatitis C virus; linkage-to-care; test and treat;
D O I
10.1111/jvh.13634
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
According to WHO goals, the elimination of Hepatitis C Virus (HCV) by 2030 requires enhancing and simplifying HCV testing. Our aim was to create a model to assess and compare different strategies for HCV testing, linkage to care and treatment among people who access harm reduction centres (HRC) and Addiction Centres in Catalonia. A decision tree model was designed to evaluate two strategies: Hepatitis C Point-of-care (POC) "test and treat", at the community versus standard-of-care (SOC), in which HCV testing was performed at community and therapy at the hospital. Both strategies were assessed separately in HRCs (6,878 users) and Addiction Centres (13,778 users). with a time horizon of 18 months. Healthcare outcomes were HCV testing, linkage to care, treatment outcomes and reinfection rate. HCV testing was performed in 3,178 (46%) of the HRC users. Compared with SOC, POC increased access to treatment by 57% (63% vs. 6%). SVR rates were 64% in POC vs. 23% in SOC. Reinfection rates were 21% with POC compared to 24% with SOC. With POC, losses to follow-up were reduced by 41%. In the Addiction Centres, 12,566 users (91%) were screened using the two strategies. Compared to the SOC, POC increased access to treatment and linkage to care by 19% along with SVR at the same rate. Reinfection rates decreased by 6%. Thus, the implementation of a POC "test and treat" strategy at HRCs and Addiction Centres has shown to be an effective public health strategy to help eliminating HCV in accordance with WHO goal.
引用
收藏
页码:227 / 230
页数:4
相关论文
共 50 条
  • [21] RAPID HEPATITIS C POINT-OF-CARE RNA TESTING AND TREATMENT AT AN INTEGRATED SUPERVISED CONSUMPTION SITE IN TORONTO, CANADA
    Feld, Jordan J.
    Lettner, Bernadette
    Mason, Kate
    Mandel, Erin
    Rosborough, Sushi
    Altenberg, Jason
    Powis, Jeff
    HEPATOLOGY, 2019, 70 : 973A - 974A
  • [22] IMPROVING HEPATITIS C TESTING AND TREATMENT USING EFFECTIVE INTERVENTIONS TO ACHIEVE HEPATITIS C VIRUS ELIMINATION
    Cunningham, Evan
    DRUG AND ALCOHOL REVIEW, 2021, 40 : S28 - S28
  • [23] Harm reduction, hepatitis C and opioid pharmacotherapy: an opportunity for integrated hepatitis C virus-specific harm reduction
    Hallinan, Richard
    Byrne, Andrew
    Dore, Gregory J.
    DRUG AND ALCOHOL REVIEW, 2007, 26 (04) : 437 - 443
  • [24] Progress in hepatitis C testing as a part of the hepatitis C elimination program in Georgia
    Gamkrelidze, Amiran
    Gabunia, Tamar
    Turdziladze, Alexander
    Khonelidze, Irma
    Tsereteli, Maia
    Getia, Vladimer
    Adamia, Ekaterine
    Kuchuloria, Tinatin
    Tskhomelidze, Irina
    Nasrullah, Muazzam
    Shadaker, Shaun
    Gvinjilia, Lia
    Averhoff, Francisco
    JOURNAL OF HEPATOLOGY, 2020, 73 : S789 - S790
  • [25] Certification program of Addiction Centres for hepatitis C virus elimination in Spain. HepCelentes Project
    Colom, Joan
    Torrens, Marta
    Rodriguez-Cejas, Angeles
    Aguilar, Ignacio
    Alvarez-Crespo, Rocio
    Armenteros, Lorenzo
    Ayala, Victoria
    Cantero, Helena
    Casado, Miguel Angel
    Crespo, Javier
    Estevez, Joaquin
    Garcia-Samaniego, Javier
    Hernandez-Guerra, Manuel
    Mur, Carlos
    Perez-Bech, Eva
    Ricote, Mercedes
    Pineda, Juan Antonio
    ADICCIONES, 2024, 36 (02)
  • [26] Molecular Point-of-Care Testing for Hepatitis C: Available Technologies, Pipeline, and Promising Future Directions
    Reipold, Elena Ivanova
    Shilton, Sonjelle
    Donolato, Marco
    Suarez, Marta Fernandez
    JOURNAL OF INFECTIOUS DISEASES, 2024, 229 : S342 - S349
  • [27] Point-of-care hepatitis C testing from needle and syringe programs: An Australian feasibility study
    Williams, Bridget
    Howell, Jessica
    Doyle, Joseph
    Thompson, Alexander J.
    Draper, Bridget
    Layton, Chloe
    Latham, Ned
    Bramwell, Frances
    Membrey, Dean
    Mcpherson, Maggie
    Roney, Janine
    Stoove, Mark
    Hellard, Margaret E.
    Pedrana, Alisa
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2019, 72 : 91 - 98
  • [28] Hepatitis C prevention and true harm reduction
    Madden, Annie
    Cavalieri, Walter
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2007, 18 (05) : 335 - 337
  • [29] Stressful point-of-care rapid testing for human immunodeficiency virus, hepatitis C virus, and syphilis
    Reynolds, Grace L.
    Fisher, Dennis G.
    Brocato, Jo
    van Otterloo, Lucy
    Khahlil, Khaloud
    Huckabay, Loucine
    INTERNATIONAL JOURNAL OF STD & AIDS, 2017, 28 (10) : 975 - 984
  • [30] Assessing Molecular Point-of-Care Testing and Dried Blood Spot for Hepatitis C Virus Screening in People Who Inject Drugs
    Chevaliez, Stephane
    Wlassow, Melanie
    Volant, Johann
    Roudot-Thoraval, Francoise
    Bachelard, Antoine
    Poiteau, Lila
    Trabut, Jean-Baptiste
    Hezode, Christophe
    Bourdel, Anne
    Dominguez, Stephanie
    OPEN FORUM INFECTIOUS DISEASES, 2020, 7 (06):